Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it has expanded its intellectual property portfolio in medical robotics with the issuance of 30 additional U.S. patents since January 2011. Hansen Medical also shares rights to more than 250 issued U.S. patents relating to medical robotics through licensing arrangement with third parties.
Certain of the patents provide additional coverage for Hansen Medical's Magellan Robotic System, which is designed to treat a variety of peripheral vascular diseases and is currently being commercialized in the United States and the European Union. Several of the patents also provide additional coverage for Hansen Medical's Sensei X Robotic Catheter System, while others provide innovative solutions for potential future advancements to its robotic technologies.
"Patent protection is very important in our industry," said Bruce J Barclay, Hansen Medical president and chief executive officer. "Significant value at Hansen Medical lies in the intellectual property assets we have developed for use in our products and that can be used across a number of platforms outside of our core markets. We continue to work diligently to build patent protection covering the innovative work being performed by our talented engineers and scientists at the company."
Specifically, the 30 additional patents received by Hansen Medical are U.S. Patent No. 7,867,241, titled Flexible Instrument; 7,905,828, Flexible Instrument; 7,918,861, Flexible Instrument; 7,947,050, Surgical Instrument Coupling Mechanism; 7,972,298, Robotic Catheter System; 7,974,681, Robotic Catheter System; 7,901,399, Interchangeable Surgical Instrument; 7,922,693, Apparatus Systems and Methods for Flushing Gas from a Catheter of a Robotic Catheter System; 7,931,586, Flexible Instrument; 7,935,059, System and Method for 3-D Imaging; 7,947,051, Surgical Instrument Coupling Mechanism; 7,955,316, Coaxial Catheter System; 7,959,557, Robotic Medical Instrument System; 7,963,288, Robotic Catheter System; 7,976,539, System and Method for Denaturing and Fixing Collagenous Tissue; 8,005,537, Robotically Controlled Intravascular Tissue Injection System; 8,007,511, Surgical Instrument Design; 8,021,326, Instrument Driver for Robotic Catheter System; 8,041,413, Systems and Methods for Three-Dimensional Ultrasound Mapping; 8,052,621, Method of Sensing Forces on a Working Instrument; 8,052,636, Robotic Catheter System and Methods; 8,083,691, Apparatus and Method for Sensing Force; 8,092,397, Apparatus for Measuring Distal Forces on a Working Instrument; 8,108,069, Robotic Catheter System and Methods; 8,114,097, Flexible Instrument; 8,146,874, Mounting Support Assembly for Suspending a Medical Instrument Driver Above an Operating Table; 8,160,690, System and Method for Determining Electrode-Tissue Contact Based on Amplitude Modulation of Sensed Signal; 8,172,747, Balloon Visualization for Traversing a Tissue Wall; 8,187,229, Coaxial Catheter System; and 8,190,238, Robotic Catheter System and Methods.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the global leader in intravascular robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan Robotic System, NorthStar Robotic Catheter and related accessories, which are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, have undergone both CE marking and 510(k) clearance and are commercially available in the European Union, and the U.S. In the European Union, the Company's Sensei X Robotic Catheter System and Artisan Control Catheter are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S. the Company's Sensei X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X System and Artisan Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established.
Additional information can be found at www.hansenmedical.com.
This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the potential benefits of our technology and the value of our intellectual property portfolio. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the uncertain timelines for the sales cycle for newly introduced products; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to maintain our remedial actions over previously reported material weaknesses in internal controls over financial reporting; our ability to manage expenses and cash flow, and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 filed with the SEC on August 9, 2012 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), Sensei and Lynx are registered trademarks, and Magellan and NorthStar are trademarks of Hansen Medical, Inc. in the United States and other countries.